Top 10 Biopharma Company

  • A top-10 global biopharma company advancing a monoclonal antibody for atopic dermatitis faced a familiar challenge: rigid, template-driven planning processes were producing brand strategies that lacked differentiation and impact. With launch on the horizon, leadership recognized the need for a more agile, insight-driven approach.

  • Strategic Partnership at the Global Level Collaborating with the global commercial and medical teams, we:

    • Led the full development of the 2026 brand plan for the lead indication (atopic dermatitis), incorporating global research, internal insight, and landscape evolution.

    • Facilitated cross-functional workstreams covering situation analysis, decision-making drivers, segmentation, and value proposition refinement.

    • Created a visual brand narrative and strategy presentation to align senior leadership and global affiliates.

    • Supported the integration of medical, market access, and commercial perspectives through tailored session design and stakeholder engagement.

    Driving U.S. Localization and Affiliate Alignment Following the successful global work, the client engaged us to help translate the global brand plan into an actionable U.S. market strategy:

    • Designed and led a U.S. cross-functional workshop focused on localizing strategic pillars, experience journeys, and value narratives.

    • Facilitated the alignment of strategic imperatives and critical success factors (CSFs) across medical, commercial, and payer-facing teams. • Supported collaboration with external agency partners to ensure downstream planning and execution were fully connected to the brand's strategic foundation.

  • This engagement demonstrates the value of continuity from global strategy development to local execution support. By embedding strategic alignment early and enabling local adaptation through facilitated engagement, we helped ensure both rigor and relevance in launch preparation across geographies.

    • Delivered a fully aligned and globally validated 2026 brand strategy for a high-priority immunology launch.

    • Enabled rapid U.S. adaptation of the global plan, ensuring local relevance while maintaining strategic coherence.

    • Fostered greater engagement, ownership, and clarity among U.S. cross-functional teams preparing for their first brand plan cycle on this asset.